The authors employed simultaneous two-step modifications to engineer MSCs and MSC-derived exosomes to create exosomes overexpressing the fused protein lysosome-associated membrane protein 2-interleukin 3 and hematopoietic cell E-selectin/L-selectin ligand.
[Cancer Letters]